The proposed flare criteria may become useful but require validation in other interferonopathies including Aicardi-Goutières syndrome (AGS) and stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI) when treatments become available that achieve similar disease control to JAKis in CANDLE/PRAAS. This evidence concerns the gene STING1 and Aicardi-Goutières syndrome.